kabutan

Immuno-Biological Lab, The Current Fiscal Year Ordinary Profit Revised Upward to an Unexpected 44% Increase, Highest in Twenty Two Terms

Tue Feb 18, 2025 3:30 pm JST Revision

4570 Immuno-Biological Laboratories Co., Ltd. 【J-GAAP】

Guidance Update Report

Immuno-Biological Laboratories Co., Ltd. <4570> [TSE Growth] announced a performance revision after the market closed on February 18th (15:30). The consolidated ordinary profit for the fiscal year ending March 2025 has been revised upward 50.0%, from the previous forecast of 120 million yen to 180 million yen (compared to 125 million yen in the previous period), reaches new record high for the first time in twenty two terms, turning to a 44.0% increase in the consolidated ordinary profit outlook.

Based on the upwardly revised full-year plan announced by the company, our calculation indicates that the October to March period (2H) consolidated ordinary profit is expected to increase 2.1 times, from the previous forecast of 56 million yen to 116 million yen (compared to 95 million yen in the same period of the previous year), turning to a 22.1% increase in the consolidated ordinary profit outlook.

Kabutan News

Guidance Update

Second Half Update

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2024 Prev 481 52 56 44 4.7 0 Nov 11, 2024 J-GAAP
Oct - Mar, 2024 New 481 112 116 144 15.5 0 Feb 18, 2025 J-GAAP
Revision Rate 0.0% +115.4% +107.1% +227.3% +226.8%

Full Year Update

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2025 Prev 925 120 120 115 12.4 0 May 14, 2024 J-GAAP
Mar, 2025 New 925 180 180 215 23.1 0 Feb 18, 2025 J-GAAP
Revision Rate 0.0% +50.0% +50.0% +87.0% +86.9%

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2023 451 91 95 160 17.3 0 May 14, 2024 J-GAAP
Oct - Mar, 2024 Guidance 481 112 116 144 15.5 0 Feb 18, 2025 J-GAAP
YoY +6.7% +23.1% +22.1% -10.0% -10.4%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2023 794 57 -149 -289 -31.1 0 May 12, 2023 J-GAAP
Mar, 2024 816 104 125 186 20.1 0 May 14, 2024 J-GAAP
Mar, 2025 Guidance 925 180 180 215 23.1 0 Feb 18, 2025 J-GAAP
YoY +13.4% +73.1% +44.0% +15.6% +15.1%

Related Articles